Bristol Myers Squibb (CELG-RI) Change in Accured Expenses (2021 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Change in Accured Expenses for 6 consecutive years, with $360.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 59.14% year-over-year to $360.0 million; the TTM figure through Jun 2026 stood at -$3.8 billion (down 329.62% YoY), while the FY2025 annual figure was -$441.0 million, down 129.72% from the prior year.
• Change in Accured Expenses advanced to $360.0 million in Q2 2026 per CELG-RI's latest filing, from -$3.5 billion in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.8 billion in Q3 2024 and bottomed at -$3.5 billion in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$42.3 million across 5 years, with a median of $74.5 million in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 141.86% in 2022 and fell as far as 676.92% in 2022.
• Bristol Myers Squibb's Change in Accured Expenses stood at -$303.0 million in 2022, then jumped by 30.36% to -$211.0 million in 2023, then slumped by 91.94% to -$405.0 million in 2024, then plunged by 492.1% to -$2.4 billion in 2025, then soared by 115.01% to $360.0 million in 2026.
• Business Quant data shows CELG-RI's Change in Accured Expenses at $360.0 million in Q2 2026, -$3.5 billion in Q1 2026, and -$2.4 billion in Q4 2025.